International Journal of Virology and Molecular Biology
p-ISSN: 2163-2219 e-ISSN: 2163-2227
2018; 7(2): 33-37
doi:10.5923/j.ijvmb.20180702.02
Renaud J-J. Dechi1, 2, Thomas A. Toni1, Phillipe J-L. N’din1, 2, Jean F. N’guessan1, Emmanuel Brou1, Ahoua Aguia1, Kouadio Kouakou1, Henri Chenal1, Massara Camara-Cisse2
1Virology Laboratory, Abidjan Integrated Bioclinical Research Center (CIRBA), Abidjan, Côte d’Ivoire
2Biochimistry Laboratory, Faculty of Medical Sciences, University of Félix Houphouët-Boigny (UFHB), Abidjan, Côte d’Ivoire
Correspondence to: Thomas A. Toni, Virology Laboratory, Abidjan Integrated Bioclinical Research Center (CIRBA), Abidjan, Côte d’Ivoire.
Email: |
Copyright © 2018 The Author(s). Published by Scientific & Academic Publishing.
This work is licensed under the Creative Commons Attribution International License (CC BY).
http://creativecommons.org/licenses/by/4.0/
Protease inhibitors (PIs) select more mutations than any other class of antiretroviral drugs (ARV). The objective of our study was to determine minor and major mutations in HIV-1 protease that may decrease the efficacy of PIs in children. The determination of mutations and their interpretations were performed using ANRS techniques and algorithms (www.hivfrenchresistance.org). Sequence analysis identified 13% of children resistant to PIs. Frequent minor mutations were M36I and K20I (100% respectively), H69K (88%), L89M and I54V (75% respectively) and G16E (50%). The major mutations were V82A (75%), M46I (63%), L90M (38%) and L76V (13%). Resistance was noted to Indinavir (IDV) and Fosamprenavir/Ritonavir (FPV/r) (75% respectively), Nelfinavir (NFV) and Saquinavir/Ritonavir (SQV/r) (50% respectively), Atazanavir/Ritonavir (ATV/r) (38%) and Lopinavir/Ritonavir (LPV/r) (25%). This study identified mutations associated with PIs resistance in children. The minor mutations frequently encountered whose association with other mutations cause resistance to LPV/r and ATV/r respectively were I54V and G16E. The major mutation responsible for resistance to LPV/r was L76V. The combination of minor and major mutations frequently associated with PIs ineffectiveness was the combination of 4 mutations, I54V, V82A, L90M and M46I for LPV/r and 3 mutations, G16E, L90M and M46I for ATV/r. No resistance to DRV/r was observed, it could be a surrogate molecule.
Keywords: Resistance mutation, Child, HIV-1, Protease inhibitor, Côte d’Ivoire
Cite this paper: Renaud J-J. Dechi, Thomas A. Toni, Phillipe J-L. N’din, Jean F. N’guessan, Emmanuel Brou, Ahoua Aguia, Kouadio Kouakou, Henri Chenal, Massara Camara-Cisse, Protease Inhibitor Resistance Mutation Profile in Children on Antiretroviral Therapy for at Least Six Months in Abidjan (Côte d’Ivoire), International Journal of Virology and Molecular Biology, Vol. 7 No. 2, 2018, pp. 33-37. doi: 10.5923/j.ijvmb.20180702.02.
|
|
|
Figure 2. HIV-1 PIs resistance frequencies in the 8 resistant children included in the CIRBA study in 2012 and 2013 |